The National Health (Minimum Stockholding) Amendment Determination (No. 3) 2026, issued by the Australian Department of Health, amends the National Health (Minimum Stockholding) Determination 2023. This legislative instrument revises the minimum stockholding requirements for pharmaceuticals, impacting the supply chain and availability of medicines. The amendments are scheduled to take effect in two phases: April 1, 2026, and October 1, 2026.

Pharmaceutical manufacturers and distributors must review and comply with the updated stockholding obligations. Failure to adhere to these revised requirements could lead to penalties under the National Health Act 1953. Compliance officers should ensure their inventory management systems and supply chain strategies align with the new deadlines and stockholding levels to avoid regulatory action.